Crossmark

A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report

Crossref DOI link: https://doi.org/10.1186/s13256-017-1550-6

Published Online: 2018-02-18

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takemori, Nobuo https://orcid.org/0000-0001-9742-8385
Imai, Goro

Hoshino, Kazuo

Ooi, Akishi

Kojima, Masaru
More Information

Article History

Received: 30 October 2017

Accepted: 21 December 2017

First Online: 18 February 2018

Ethics approval and consent to participate

: The patient was fully informed of the risk of modified treatments and the theoretical basis of the treatments for MM was explained to her.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in Chief of this journal.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published map and institutional affiliations.

Document is current

Any future updates will be listed below